Abstract
BackgroundThe development of novel and effective drugs for targeted human hepatocellular carcinoma still remains a great challenge. The alkaloid nitidine chloride (NC), a component of a traditional Chinese medicine, has been shown to have anticancer properties, but doses at therapeutic levels have unacceptable side effects. Here we investigate folic acid modified D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS-FA) as a potential carrier for controlled delivery of the drug.MethodsSynthesized TPGS-FA was characterized by FTIR, UV-visible and 1H NMR spectroscopy, and TPGS loaded with NC was evaluated for its ability to induce apoptosis in Huh7 cells by Annexin V/PI and MTT assays, and observed by laser scanning confocal microscopy and inverted phase contrast microscopy.ResultsTPGS-FA/NC complexes were prepared successfully, and were homogenious with a uniform size of ~ 14 nm diameter. NC was released from the TPGS-FA/NC complexes in a controlled and sustained manner under physiological conditions (pH 7.4). Furthermore, its cytotoxicity to hepatocarcinoma cells was greater than that of free NC.ConclusionsTPGS-FA is shown to be useful carrier for drugs such as NC, and TPGS-FA/NC could potentially be a potent and safe drug for the treatment of hepatocellular carcinoma.
Highlights
The development of novel and effective drugs for targeted human hepatocellular carcinoma still remains a great challenge
FITC Annexin V apoptosis Detection Kit was purchased from Thermofish Scientific(Thermofish, waltham, USA) MTT was purchased from Beijing Solarbio Science & Technology Co., Ltd.(Solarbio, Beijing, China)
The folic acid could be used as a targeting ligand, which could help TPGSFA/nitidine chloride (NC) conjugates enter Huh7 cells via the folate receptor-mediated endocytic pathway
Summary
The development of novel and effective drugs for targeted human hepatocellular carcinoma still remains a great challenge. The alkaloid nitidine chloride (NC), a component of a traditional Chinese medicine, has been shown to have anticancer properties, but doses at therapeutic levels have unacceptable side effects. We investigate folic acid modified D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS-FA) as a potential carrier for controlled delivery of the drug. Novel drugs and effective drug delivery systems for liver cancer therapy need to be developed to overcome this chemoresistance [14]. TPGS has been shown to improve the bioavailability of certain anticancer drugs [18, 19], and has been reported have selective cytotoxic activity against cancer cells by inducing their apoptosis [20]. Optimizing the drug delivery system is a necessary procedure for enhancing the targeting of drugs to tumor cells/ tissues [21, 22]. The exact mechanism of the FR delivery system is still not fully understood, many folatemodified nano-micelles have been discovered with good therapeutic effects, because of receptormediated endocytosis [27, 30]
Full Text
Topics from this Paper
Nitidine Chloride
Apoptosis In Huh7 Cells
Inverted Phase Contrast
Unacceptable Side Effects
Confocal Microscopy
+ Show 5 more
Create a personalized feed of these topics
Get StartedTalk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Similar Papers
Dec 3, 2020
Planta Medica
Feb 1, 2022
Molecular Therapy - Oncolytics
Mar 1, 2019
BMC Pharmacology and Toxicology
Jul 12, 2022
Oncology reports
Apr 2, 2019
Die Pharmazie
Sep 1, 2020
Pharmacological Reports
Feb 1, 2018
Oncology Reports
Jun 2, 2016
Molecular Medicine Reports
Jan 29, 2016
Aging
Dec 3, 2020
BMC cancer
Sep 30, 2014
Tumor Biology
Jul 17, 2014
Chinese Medicine
Sep 29, 2022
Molecular Medicine Reports
Feb 23, 2016
International Journal of Molecular Medicine
Apr 22, 2013
BMC Pharmacology and Toxicology
BMC Pharmacology and Toxicology
Nov 25, 2023
BMC Pharmacology and Toxicology
Nov 23, 2023
BMC Pharmacology and Toxicology
Nov 22, 2023
BMC Pharmacology and Toxicology
Nov 21, 2023
BMC Pharmacology and Toxicology
Nov 20, 2023
BMC Pharmacology and Toxicology
Nov 13, 2023
BMC Pharmacology and Toxicology
Nov 9, 2023
BMC Pharmacology and Toxicology
Nov 7, 2023
BMC Pharmacology and Toxicology
Nov 3, 2023
BMC Pharmacology and Toxicology
Nov 2, 2023